Avinger Bilan de santé

Santé financière contrôle des critères 3/6

Avinger possède un total de capitaux propres de $3.9M et une dette totale de $4.2M, ce qui porte son ratio d'endettement à 107.6%. Son actif total et son passif total sont $13.6M et de $9.7M.

Informations clés

107.6%

Ratio d'endettement

US$4.17m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$5.90m
Fonds propres	US$3.88m
Total du passif	US$9.73m
Total des actifs	US$13.60m

Mises à jour récentes de la santé financière

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Nov 25

Is Avinger (NASDAQ:AVGR) A Risky Investment?

Jun 30

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de AVGR ( $11.5M ) dépassent ses passifs à court terme ( $9.5M ).

Passif à long terme: Les actifs à court terme de AVGR ( $11.5M ) dépassent ses passifs à long terme ( $223.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: AVGR dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de AVGR est passé de 98% à 107.6% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: AVGR dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: AVGR dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 3.5 % chaque année.

Avinger Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Is Avinger (NASDAQ:AVGR) A Risky Investment?

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Insufficient new directors

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avinger GAAP EPS of -$0.94 beats by $0.15, revenue of $2.13M misses by $0.25M

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

Is Avinger (NASDAQ:AVGR) A Risky Investment?

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Avinger shares fall after Q1 results fail to impress Wall Street

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Avinger Regains Compliance with Nasdaq Listing Requirements

Does Avinger (NASDAQ:AVGR) Have A Healthy Balance Sheet?

New 90-day high: US$0.89

Avinger 'Hot Penny Stock to buy' - Robinhood

New 90-day high: US$0.35

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Third quarter 2020 earnings released: US$0.079 loss per share

Revenue beats expectations, earnings disappoint

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.29

New 90-day low: US$0.29

Analysts increase EPS estimates to -US$0.69

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - US$0.67

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines